{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:04:05Z","timestamp":1792242245757,"version":"4.4.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The diagnosis of a non-metastatic parathyroid carcinoma requires the demonstration of invasive growth that defines malignancy. These include angioinvasion or vascular invasion (i.e., tumor penetrating the vessel wall and associated with thrombus or intravascular tumor cells intermixed with thrombus), lymphatic invasion, perineural (intraneural) invasion, and\/or direct invasion into adjacent anatomical structures. However, the distinction of a pT1 disease (8th edition of UICC TNM staging system) which represents a localized disease (tumor confined to the parathyroid gland or showing minimal extra-parathyroidal soft tissue invasion without direct invasion into adjacent structures) often requires meticulous microscopic examination that couples multiple levels and biomarker studies. Although the diagnostic criteria of malignancy are clearly defined, the identification of harbingers of invasive growth and distinguishing them from their mimics can pose diagnostic challenges. Several artifacts and manipulations can simulate malignancy. For example, a prior biopsy, PTH washout, ethanol injection, or any form of surgical manipulation may result in fibrosis, crush (mechanical) artifacts, or tissue distortion, which can obscure histological details and mimic invasion. Peliosis\u2014the presence of extravasated erythrocytes without an endothelial lining\u2014may simulate vascular invasion. Other common mimics include mechanically displaced intravascular tumor cells unassociated with thrombus, which can occur at the time of specimen handling. Extension of the tumor into the adjacent irregular connective tissue or pseudo-capsule can be mistaken for invasive growth. Similarly, an intrathyroidal location of the parathyroid gland adds another layer of complexity. In such cases, the boundary between the parathyroid tissue and surrounding thyroid parenchyma may not be clearly discernible, making it difficult to determine whether there is genuine invasive growth into thyroid (pT2 disease, 8th edition of UICC TNM system) or simply anatomical proximity. In addition, parathyromatosis and contour irregularities associated with long-standing secondary or tertiary hyperparathyroidism are other challenging manifestations. Atypical parathyroid tumors (WHO 2022) should also be clearly delineated using appropriate criteria. In summary, pathologists must be aware of the potential pitfalls that may lead to overdiagnosis of parathyroid carcinoma. A consolidated diagnostic workup, which combines multiple levels and biomarkers, is necessary to ensure diagnostic accuracy in all parathyroid tumors. This review provides practical insights on these diagnostic difficulties, illustrating common artifacts and mimics. We also discuss the relevant clinical, histological, immunohistochemical, and molecular features associated with parathyroid carcinoma, with the goal of enhancing diagnostic accuracy.<\/jats:p>","DOI":"10.1007\/s00428-025-04274-4","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:11:10Z","timestamp":1763140270000},"page":"159-171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Avoiding overdiagnosis of parathyroid carcinoma"],"prefix":"10.1007","volume":"488","author":[{"given":"Carl Christofer","family":"Juhlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0469-2801","authenticated-orcid":false,"given":"Ozgur","family":"Mete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"4274_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00731","volume":"10","author":"A Akirov","year":"2019","unstructured":"Akirov A, Asa SL, Larouche V et al (2019) The clinicopathological spectrum of parathyroid carcinoma. Front Endocrinol (Lausanne) 10:731. https:\/\/doi.org\/10.3389\/fendo.2019.00731","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4274_CR2","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1210\/jc.2011-1571","volume":"96","author":"A Harari","year":"2011","unstructured":"Harari A, Waring A, Fernandez-Ranvier G et al (2011) Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab 96:3679\u20133686. https:\/\/doi.org\/10.1210\/jc.2011-1571","journal-title":"J Clin Endocrinol Metab"},{"key":"4274_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s12022-022-09709-1","volume":"33","author":"LA Erickson","year":"2022","unstructured":"Erickson LA, Mete O, Juhlin CC et al (2022) Overview of the 2022 WHO classification of parathyroid tumors. Endocr Pathol 33:64\u201389. https:\/\/doi.org\/10.1007\/s12022-022-09709-1","journal-title":"Endocr Pathol"},{"key":"4274_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004144","author":"C Lenschow","year":"2020","unstructured":"Lenschow C, Schr\u00e4gle S, Kircher S et al (2020) Clinical presentation, treatment, and outcome of parathyroid carcinoma: results of the NEKAR retrospective international multicenter study. Ann Surg. https:\/\/doi.org\/10.1097\/SLA.0000000000004144","journal-title":"Ann Surg"},{"key":"4274_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2018.09.013","volume":"101247","author":"BC Silva","year":"2018","unstructured":"Silva BC, Cusano NE, Bilezikian JP (2018) Primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab 101247:101247. https:\/\/doi.org\/10.1016\/j.beem.2018.09.013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"4274_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/joim.12840","volume":"285","author":"I-L Nilsson","year":"2019","unstructured":"Nilsson I-L (2019) Primary hyperparathyroidism: should surgery be performed on all patients? Current evidence and residual uncertainties. J Intern Med 285:149\u2013164. https:\/\/doi.org\/10.1111\/joim.12840","journal-title":"J Intern Med"},{"key":"4274_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1009516","volume":"14","author":"A Bhan","year":"2023","unstructured":"Bhan A, Athimulam S, Kumari P et al (2023) Large parathyroid adenomas: potential mechanisms to reconcile adenoma size and disease phenotype. Front Endocrinol (Lausanne) 14:1009516. https:\/\/doi.org\/10.3389\/fendo.2023.1009516","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4274_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/jclinpath-2015-203186","volume":"68","author":"K Duan","year":"2015","unstructured":"Duan K, Gomez Hernandez K, Mete O (2015) Clinicopathological correlates of hyperparathyroidism. J Clin Pathol 68:771\u2013787. https:\/\/doi.org\/10.1136\/jclinpath-2015-203186","journal-title":"J Clin Pathol"},{"key":"4274_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12022-020-09656-9","volume":"32","author":"CC Juhlin","year":"2021","unstructured":"Juhlin CC, Erickson LA (2021) Genomics and epigenomics in parathyroid neoplasia: from bench to surgical pathology practice. Endocr Pathol 32:17\u201334. https:\/\/doi.org\/10.1007\/s12022-020-09656-9","journal-title":"Endocr Pathol"},{"key":"4274_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12022-018-9527-6","volume":"29","author":"LA Erickson","year":"2018","unstructured":"Erickson LA, Mete O (2018) Immunohistochemistry in diagnostic parathyroid pathology. Endocr Pathol 29:113\u2013129. https:\/\/doi.org\/10.1007\/s12022-018-9527-6","journal-title":"Endocr Pathol"},{"key":"4274_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0046-8177(95)90028-4","volume":"26","author":"GC Abbona","year":"1995","unstructured":"Abbona GC, Papotti M, Gasparri G, Bussolati G (1995) Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining. Hum Pathol 26:135\u2013138. https:\/\/doi.org\/10.1016\/0046-8177(95)90028-4","journal-title":"Hum Pathol"},{"key":"4274_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s002689900567","volume":"23","author":"F Farnebo","year":"1999","unstructured":"Farnebo F, Auer G, Farnebo LO et al (1999) Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease. World J Surg 23:68\u201374. https:\/\/doi.org\/10.1007\/s002689900567","journal-title":"World J Surg"},{"key":"4274_CR13","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41379-019-0252-6","volume":"32","author":"CC Juhlin","year":"2019","unstructured":"Juhlin CC, Nilsson I-L, Lagerstedt-Robinson K et al (2019) Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center. Mod Pathol 32:1082\u20131094. https:\/\/doi.org\/10.1038\/s41379-019-0252-6","journal-title":"Mod Pathol"},{"issue":"Suppl 1","key":"4274_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.5146\/tjpath.2015.01316","volume":"31","author":"K Duan","year":"2015","unstructured":"Duan K, Mete \u00d6 (2015) Parathyroid carcinoma: diagnosis and clinical implications. Turk Patoloji Derg 31(Suppl 1):80\u201397. https:\/\/doi.org\/10.5146\/tjpath.2015.01316","journal-title":"Turk Patoloji Derg"},{"issue":"7","key":"4274_CR15","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.pathol.2021.02.011","volume":"53","author":"CC Juhlin","year":"2021","unstructured":"Juhlin CC, Nilsson I-L, Falhammar H, Zedenius J (2021) Institutional characterisation of water clear cell parathyroid adenoma: a rare entity often unrecognised by TC-99m-sestamibi scintigraphy. Pathology 53(7):852. https:\/\/doi.org\/10.1016\/j.pathol.2021.02.011","journal-title":"Pathology"},{"key":"4274_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12022-020-09616-3","volume":"31","author":"CC Juhlin","year":"2020","unstructured":"Juhlin CC, Falhammar H, Zedenius J et al (2020) Lipoadenoma of the parathyroid gland: characterization of an institutional series spanning 28 years. Endocr Pathol 31:156\u2013165. https:\/\/doi.org\/10.1007\/s12022-020-09616-3","journal-title":"Endocr Pathol"},{"key":"4274_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4158\/EP.12.2.131","volume":"12","author":"LS Chow","year":"2006","unstructured":"Chow LS, Erickson LA, Abu-Lebdeh HS, Wermers RA (2006) Parathyroid lipoadenomas: a rare cause of primary hyperparathyroidism. Endocr Pract 12:131\u2013136. https:\/\/doi.org\/10.4158\/EP.12.2.131","journal-title":"Endocr Pract"},{"key":"4274_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12022-015-9404-5","volume":"27","author":"MD Hyrcza","year":"2016","unstructured":"Hyrcza MD, Sarg\u0131n P, Mete O (2016) Parathyroid lipoadenoma: a clinicopathological diagnosis and possible trap for the unaware pathologist. Endocr Pathol 27:34\u201341. https:\/\/doi.org\/10.1007\/s12022-015-9404-5","journal-title":"Endocr Pathol"},{"key":"4274_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12022-012-9222-y","volume":"23","author":"BM Erovic","year":"2012","unstructured":"Erovic BM, Harris L, Jamali M et al (2012) Biomarkers of parathyroid carcinoma. Endocr Pathol 23:221\u2013231. https:\/\/doi.org\/10.1007\/s12022-012-9222-y","journal-title":"Endocr Pathol"},{"key":"4274_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12022-019-09603-3","volume":"31","author":"H Gucer","year":"2020","unstructured":"Gucer H, Caliskan S, Kefeli M, Mete O (2020) Do you know the details of your PAX8 antibody? Monoclonal PAX8 (MRQ-50) is not expressed in a series of 45 medullary thyroid carcinomas. Endocr Pathol 31:33\u201338. https:\/\/doi.org\/10.1007\/s12022-019-09603-3","journal-title":"Endocr Pathol"},{"key":"4274_CR21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/jcem.86.2.7207","volume":"86","author":"E Shane","year":"2001","unstructured":"Shane E (2001) Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab 86:485\u2013493. https:\/\/doi.org\/10.1210\/jcem.86.2.7207","journal-title":"J Clin Endocrinol Metab"},{"key":"4274_CR22","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/ng1048","volume":"32","author":"JD Carpten","year":"2002","unstructured":"Carpten JD, Robbins CM, Villablanca A et al (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32:676\u2013680. https:\/\/doi.org\/10.1038\/ng1048","journal-title":"Nat Genet"},{"key":"4274_CR23","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1210\/jcem.81.12.8954016","volume":"81","author":"BT Teh","year":"1996","unstructured":"Teh BT, Farnebo F, Kristoffersson U et al (1996) Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. J Clin Endocrinol Metab 81:4204\u20134211. https:\/\/doi.org\/10.1210\/jcem.81.12.8954016","journal-title":"J Clin Endocrinol Metab"},{"key":"4274_CR24","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1210\/jcem.83.6.4896","volume":"83","author":"BT Teh","year":"1998","unstructured":"Teh BT, Farnebo F, Twigg S et al (1998) Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families. J Clin Endocrinol Metab 83:2114\u20132120. https:\/\/doi.org\/10.1210\/jcem.83.6.4896","journal-title":"J Clin Endocrinol Metab"},{"key":"4274_CR25","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/sj.onc.1209893","volume":"26","author":"KJ Bradley","year":"2007","unstructured":"Bradley KJ, Bowl MR, Williams SE et al (2007) Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal. Oncogene 26:1213\u20131221. https:\/\/doi.org\/10.1038\/sj.onc.1209893","journal-title":"Oncogene"},{"key":"4274_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/324964","volume":"2010","author":"CC Juhlin","year":"2010","unstructured":"Juhlin CC, H\u00f6\u00f6g A (2010) Parafibromin as a diagnostic instrument for parathyroid carcinoma-lone ranger or part of the posse? Int J Endocrinol 2010:324964. https:\/\/doi.org\/10.1155\/2010\/324964","journal-title":"Int J Endocrinol"},{"key":"4274_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/1541-7786.MCR-06-0129","volume":"5","author":"L Lin","year":"2007","unstructured":"Lin L, Czapiga M, Nini L et al (2007) Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function. Mol Cancer Res 5:183\u2013193. https:\/\/doi.org\/10.1158\/1541-7786.MCR-06-0129","journal-title":"Mol Cancer Res"},{"key":"4274_CR28","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1097\/01.pas.0000209827.39477.4f","volume":"30","author":"AJ Gill","year":"2006","unstructured":"Gill AJ, Clarkson A, Gimm O et al (2006) Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30:1140\u20131149. https:\/\/doi.org\/10.1097\/01.pas.0000209827.39477.4f","journal-title":"Am J Surg Pathol"},{"key":"4274_CR29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s12022-010-9121-z","volume":"21","author":"CC Juhlin","year":"2010","unstructured":"Juhlin CC, Nilsson I-L, Johansson K et al (2010) Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol 21:166\u2013177. https:\/\/doi.org\/10.1007\/s12022-010-9121-z","journal-title":"Endocr Pathol"},{"key":"4274_CR30","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1530\/EJE-06-0720","volume":"156","author":"F Cetani","year":"2007","unstructured":"Cetani F, Ambrogini E, Viacava P et al (2007) Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol 156:547\u2013554. https:\/\/doi.org\/10.1530\/EJE-06-0720","journal-title":"Eur J Endocrinol"},{"key":"4274_CR31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1677\/ERC-07-0021","volume":"14","author":"CC Juhlin","year":"2007","unstructured":"Juhlin CC, Villablanca A, Sandelin K et al (2007) Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer 14:501\u2013512. https:\/\/doi.org\/10.1677\/ERC-07-0021","journal-title":"Endocr Relat Cancer"},{"key":"4274_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00428-010-1032-3","volume":"459","author":"CC Juhlin","year":"2011","unstructured":"Juhlin CC, Haglund F, Obara T et al (2011) Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours. Virchows Arch 459:47\u201353. https:\/\/doi.org\/10.1007\/s00428-010-1032-3","journal-title":"Virchows Arch"},{"key":"4274_CR33","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001017","author":"AJ Gill","year":"2018","unstructured":"Gill AJ, Lim G, Cheung VKY et al (2018) Parafibromin-deficient (HPT-JT type, CDC73 mutated) parathyroid tumors demonstrate distinctive morphologic features. Am J Surg Pathol. https:\/\/doi.org\/10.1097\/PAS.0000000000001017","journal-title":"Am J Surg Pathol"},{"key":"4274_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12022-024-09804-5","volume":"35","author":"CC Juhlin","year":"2024","unstructured":"Juhlin CC (2024) Not all parafibromin deficiency relates to parathyroid carcinoma: the role of morphological assessment. Endocr Pathol 35:84\u201387. https:\/\/doi.org\/10.1007\/s12022-024-09804-5","journal-title":"Endocr Pathol"},{"key":"4274_CR35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1677\/erc.1.01058","volume":"13","author":"C Juhlin","year":"2006","unstructured":"Juhlin C, Larsson C, Yakoleva T et al (2006) Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr Relat Cancer 13:509\u2013523. https:\/\/doi.org\/10.1677\/erc.1.01058","journal-title":"Endocr Relat Cancer"},{"key":"4274_CR36","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1097\/00000478-199308000-00007","volume":"17","author":"L Bondeson","year":"1993","unstructured":"Bondeson L, Sandelin K, Grimelius L (1993) Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol 17:820\u2013829. https:\/\/doi.org\/10.1097\/00000478-199308000-00007","journal-title":"Am J Surg Pathol"},{"key":"4274_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-025-09867-y","volume":"36","author":"U Mortara","year":"2025","unstructured":"Mortara U, Orlando G, Volante M et al (2025) Reticulin framework assessment in neoplastic endocrine pathology. Endocr Pathol 36:21. https:\/\/doi.org\/10.1007\/s12022-025-09867-y","journal-title":"Endocr Pathol"},{"key":"4274_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-023-01368-y","volume":"18","author":"X Hu","year":"2023","unstructured":"Hu X, He S, Jiang X et al (2023) Reticular fibre structure in the differential diagnosis of parathyroid neoplasms. Diagn Pathol 18:79. https:\/\/doi.org\/10.1186\/s13000-023-01368-y","journal-title":"Diagn Pathol"},{"key":"4274_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12022-023-09755-3","volume":"34","author":"S La Rosa","year":"2023","unstructured":"La Rosa S (2023) Diagnostic, prognostic, and predictive role of Ki67 proliferative index in neuroendocrine and endocrine neoplasms: past, present, and future. Endocr Pathol 34:79\u201397. https:\/\/doi.org\/10.1007\/s12022-023-09755-3","journal-title":"Endocr Pathol"},{"key":"4274_CR40","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJM199403173301105","volume":"330","author":"VL Cryns","year":"1994","unstructured":"Cryns VL, Thor A, Xu HJ et al (1994) Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 330:757\u2013761. https:\/\/doi.org\/10.1056\/NEJM199403173301105","journal-title":"N Engl J Med"},{"key":"4274_CR41","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1385\/ep:11:2:109","volume":"11","author":"LA Erickson","year":"2000","unstructured":"Erickson LA (2000) p27(kip1) and other cell-cycle protein expression in normal and neoplastic endocrine tissues. Endocr Pathol 11:109\u2013122. https:\/\/doi.org\/10.1385\/ep:11:2:109","journal-title":"Endocr Pathol"},{"key":"4274_CR42","first-page":"169","volume":"11","author":"LA Erickson","year":"1998","unstructured":"Erickson LA, Jin L, Wollan PC et al (1998) Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 11:169\u2013174","journal-title":"Mod Pathol"},{"key":"4274_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009472","volume":"5","author":"CC Juhlin","year":"2010","unstructured":"Juhlin CC, Kiss NB, Villablanca A et al (2010) Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours. PLoS ONE 5:e9472. https:\/\/doi.org\/10.1371\/journal.pone.0009472","journal-title":"PLoS ONE"},{"key":"4274_CR44","first-page":"12","volume":"10","author":"MP Vargas","year":"1997","unstructured":"Vargas MP, Vargas HI, Kleiner DE, Merino MJ (1997) The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors. Mod Pathol 10:12\u201317","journal-title":"Mod Pathol"},{"key":"4274_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1053\/hupa.2003.55","volume":"34","author":"A Stojadinovic","year":"2003","unstructured":"Stojadinovic A, Hoos A, Nissan A et al (2003) Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. Hum Pathol 34:54\u201364. https:\/\/doi.org\/10.1053\/hupa.2003.55","journal-title":"Hum Pathol"},{"key":"4274_CR46","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s12022-019-09592-3","volume":"30","author":"AM Silva-Figueroa","year":"2019","unstructured":"Silva-Figueroa AM, Bassett R, Christakis I et al (2019) Using a novel diagnostic nomogram to differentiate malignant from benign parathyroid neoplasms. Endocr Pathol 30:285\u2013296. https:\/\/doi.org\/10.1007\/s12022-019-09592-3","journal-title":"Endocr Pathol"},{"key":"4274_CR47","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92061","volume":"2","author":"C Pandya","year":"2017","unstructured":"Pandya C, Uzilov AV, Bellizzi J et al (2017) Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight 2:e92061. https:\/\/doi.org\/10.1172\/jci.insight.92061","journal-title":"JCI Insight"},{"key":"4274_CR48","doi-asserted-by":"publisher","first-page":"E360","DOI":"10.1210\/jc.2014-3238","volume":"100","author":"W Yu","year":"2015","unstructured":"Yu W, McPherson JR, Stevenson M et al (2015) Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion. J Clin Endocrinol Metab 100:E360-364. https:\/\/doi.org\/10.1210\/jc.2014-3238","journal-title":"J Clin Endocrinol Metab"},{"key":"4274_CR49","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1634\/theoncologist.2018-0334","volume":"24","author":"H Kang","year":"2019","unstructured":"Kang H, Pettinga D, Schubert AD et al (2019) Genomic profiling of parathyroid carcinoma reveals genomic alterations suggesting benefit from therapy. Oncologist 24:791\u2013797. https:\/\/doi.org\/10.1634\/theoncologist.2018-0334","journal-title":"Oncologist"},{"key":"4274_CR50","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s00432-019-02945-9","volume":"145","author":"M Kutahyalioglu","year":"2019","unstructured":"Kutahyalioglu M, Nguyen HT, Kwatampora L et al (2019) Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol 145:1977\u20131986. https:\/\/doi.org\/10.1007\/s00432-019-02945-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"4274_CR51","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s12022-021-09686-x","volume":"32","author":"YA Hong","year":"2021","unstructured":"Hong YA, Park KC, Kim BK et al (2021) Analyzing genetic differences between sporadic primary and secondary\/tertiary hyperparathyroidism by targeted next-generation panel sequencing. Endocr Pathol 32:501\u2013512. https:\/\/doi.org\/10.1007\/s12022-021-09686-x","journal-title":"Endocr Pathol"},{"key":"4274_CR52","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12022-024-09836-x","volume":"35","author":"O Mete","year":"2024","unstructured":"Mete O, Boucher A, Schrader KA et al (2024) Consensus statement: recommendations on actionable biomarker testing for thyroid cancer management. Endocr Pathol 35:293\u2013308. https:\/\/doi.org\/10.1007\/s12022-024-09836-x","journal-title":"Endocr Pathol"},{"key":"4274_CR53","doi-asserted-by":"publisher","first-page":"L9","DOI":"10.1530\/ERC-15-0121","volume":"22","author":"F Haglund","year":"2015","unstructured":"Haglund F, Juhlin CC, Brown T et al (2015) TERT promoter mutations are rare in parathyroid tumors. Endocr Relat Cancer 22:L9\u2013L11. https:\/\/doi.org\/10.1530\/ERC-15-0121","journal-title":"Endocr Relat Cancer"},{"key":"4274_CR54","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3892\/ijmm_00000286","volume":"24","author":"N Osawa","year":"2009","unstructured":"Osawa N, Onoda N, Kawajiri H et al (2009) Diagnosis of parathyroid carcinoma using immunohistochemical staining against hTERT. Int J Mol Med 24:733\u2013741. https:\/\/doi.org\/10.3892\/ijmm_00000286","journal-title":"Int J Mol Med"},{"key":"4274_CR55","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/gcc.20895","volume":"50","author":"LF Starker","year":"2011","unstructured":"Starker LF, Svedlund J, Udelsman R et al (2011) The DNA methylome of benign and malignant parathyroid tumors. Genes Chromosomes Cancer 50:735\u2013745. https:\/\/doi.org\/10.1002\/gcc.20895","journal-title":"Genes Chromosomes Cancer"},{"key":"4274_CR56","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1677\/ERC-09-0291","volume":"17","author":"MA Hahn","year":"2010","unstructured":"Hahn MA, Howell VM, Gill AJ et al (2010) CDC73\/HRPT2 CpG island hypermethylation and mutation of 5\u2019-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocr Relat Cancer 17:273\u2013282. https:\/\/doi.org\/10.1677\/ERC-09-0291","journal-title":"Endocr Relat Cancer"},{"key":"4274_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-016-0197-2","volume":"8","author":"E Barazeghi","year":"2016","unstructured":"Barazeghi E, Gill AJ, Sidhu S et al (2016) 5-hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma. Clin Epigenetics 8:31. https:\/\/doi.org\/10.1186\/s13148-016-0197-2","journal-title":"Clin Epigenetics"},{"key":"4274_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-021-02123-7","volume":"19","author":"A Galani","year":"2021","unstructured":"Galani A, Morandi R, Dimko M et al (2021) Atypical parathyroid adenoma: clinical and anatomical pathologic features. World J Surg Oncol 19:19. https:\/\/doi.org\/10.1186\/s12957-021-02123-7","journal-title":"World J Surg Oncol"},{"key":"4274_CR59","first-page":"481","volume":"34","author":"CC Juhlin","year":"2009","unstructured":"Juhlin CC, Haglund F, Villablanca A et al (2009) Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas. Int J Oncol 34:481\u2013492","journal-title":"Int J Oncol"},{"key":"4274_CR60","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s00268-014-2700-2","volume":"38","author":"PP Truran","year":"2014","unstructured":"Truran PP, Johnson SJ, Bliss RD et al (2014) Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg 38:2845\u20132854. https:\/\/doi.org\/10.1007\/s00268-014-2700-2","journal-title":"World J Surg"},{"key":"4274_CR61","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.humpath.2005.06.020","volume":"36","author":"N Bergero","year":"2005","unstructured":"Bergero N, De Pompa R, Sacerdote C et al (2005) Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 36:908\u2013914. https:\/\/doi.org\/10.1016\/j.humpath.2005.06.020","journal-title":"Hum Pathol"},{"key":"4274_CR62","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1245\/s10434-013-3288-8","volume":"21","author":"S Kruijff","year":"2014","unstructured":"Kruijff S, Sidhu SB, Sywak MS et al (2014) Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas. Ann Surg Oncol 21:426\u2013433. https:\/\/doi.org\/10.1245\/s10434-013-3288-8","journal-title":"Ann Surg Oncol"},{"key":"4274_CR63","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-25-0057","volume":"32","author":"H-S Park","year":"2025","unstructured":"Park H-S, Kim M, Jo S-Y et al (2025) Transcriptome sequencing reveals distinct atypical parathyroid tumor subtypes. Endocr Relat Cancer 32:e250057. https:\/\/doi.org\/10.1530\/ERC-25-0057","journal-title":"Endocr Relat Cancer"},{"key":"4274_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s40463-016-0178-7","volume":"46","author":"J Kim","year":"2017","unstructured":"Kim J, Horowitz G, Hong M et al (2017) The dangers of parathyroid biopsy. J Otolaryngol Head Neck Surg 46:4. https:\/\/doi.org\/10.1186\/s40463-016-0178-7","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"4274_CR65","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/dc.24923","volume":"50","author":"S Steen","year":"2022","unstructured":"Steen S, Hysek M, Zedenius J et al (2022) Cyto-morphological features of parathyroid lesions: fine-needle aspiration cytology series from an endocrine tumor referral center. Diagn Cytopathol 50:75\u201383. https:\/\/doi.org\/10.1002\/dc.24923","journal-title":"Diagn Cytopathol"},{"key":"4274_CR66","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1136\/jcp.2005.029017","volume":"59","author":"S Alwaheeb","year":"2006","unstructured":"Alwaheeb S, Rambaldini G, Boerner S et al (2006) Worrisome histologic alterations following fine-needle aspiration of the parathyroid. J Clin Pathol 59:1094\u20131096. https:\/\/doi.org\/10.1136\/jcp.2005.029017","journal-title":"J Clin Pathol"},{"key":"4274_CR67","volume-title":"Survival guide to endocrine pathology","author":"SL Asa","year":"2020","unstructured":"Asa SL (2020) Survival guide to endocrine pathology. Innovative Science Press, Arlington"},{"key":"4274_CR68","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s12022-023-09759-z","volume":"34","author":"AS Tischler","year":"2023","unstructured":"Tischler AS, LiVolsi VA, Asa SL (2023) Insights obtained from the nontumorous glandular tissue in patients with endocrine tumors. Endocr Pathol 34:393\u2013405. https:\/\/doi.org\/10.1007\/s12022-023-09759-z","journal-title":"Endocr Pathol"},{"key":"4274_CR69","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.surg.2023.06.061","volume":"175","author":"JK Knepprath","year":"2024","unstructured":"Knepprath JK, McHenry CR (2024) How often are intrathyroidal parathyroid glands a cause of primary hyperparathyroidism, and how should they be managed? Surgery 175:794\u2013798. https:\/\/doi.org\/10.1016\/j.surg.2023.06.061","journal-title":"Surgery"},{"key":"4274_CR70","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1308\/rcsann.2019.0105","volume":"101","author":"M Haciyanli","year":"2019","unstructured":"Haciyanli M, Karaisli S, Gucek Haciyanli S et al (2019) Parathyromatosis: a very rare cause of recurrent primary hyperparathyroidism - case report and review of the literature. Ann R Coll Surg Engl 101:e178\u2013e183. https:\/\/doi.org\/10.1308\/rcsann.2019.0105","journal-title":"Ann R Coll Surg Engl"},{"key":"4274_CR71","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s12105-020-01281-6","volume":"15","author":"JJ Schulte","year":"2021","unstructured":"Schulte JJ, Pease G, Taxy JB et al (2021) Distinguishing parathyromatosis, atypical parathyroid adenomas, and parathyroid carcinomas utilizing histologic and clinical features. Head Neck Pathol 15:727\u2013736. https:\/\/doi.org\/10.1007\/s12105-020-01281-6","journal-title":"Head Neck Pathol"},{"key":"4274_CR72","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1744-9987.2008.00594.x","volume":"12","author":"Y Wada","year":"2008","unstructured":"Wada Y, Kunimura T, Sato S et al (2008) Proliferating potential and apoptosis in the development of secondary hyperparathyroidism: a study based on Ki-67 immunohistochemical staining and the terminal dUTP nick-end labeling assay. Ther Apher Dial 12:319\u2013328. https:\/\/doi.org\/10.1111\/j.1744-9987.2008.00594.x","journal-title":"Ther Apher Dial"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04274-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04274-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04274-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:54:01Z","timestamp":1770274441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04274-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4274"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04274-4","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}